The market keeps squeezing short sellers out of their biotech positions and rewarding bulls with big breakouts.
Knowing this, our strategy is simple. We want to keep buying the best-looking and most heavily-shorted biotech stocks.
Today, we're covering one that has rallied nearly 200% since late last year. Despite this extreme upside momentum, the stock still has a massive short interest.
With the stock resolving a multi-year accumulation pattern, we think this short squeeze has plenty of room to run. To get back to the all-time highs from just a few years ago, it would require about a 10x.
We're looking for something much smaller and quicker for now, but you never know!
Let's talk about how we're trading our latest Freshly Squeezed setup.
You need to have a subscription to access this content in full.
